全文获取类型
收费全文 | 321691篇 |
免费 | 19658篇 |
国内免费 | 430篇 |
专业分类
耳鼻咽喉 | 4472篇 |
儿科学 | 10946篇 |
妇产科学 | 10887篇 |
基础医学 | 48444篇 |
口腔科学 | 8110篇 |
临床医学 | 26955篇 |
内科学 | 61235篇 |
皮肤病学 | 6756篇 |
神经病学 | 23322篇 |
特种医学 | 12525篇 |
外国民族医学 | 43篇 |
外科学 | 50066篇 |
综合类 | 7902篇 |
现状与发展 | 1篇 |
一般理论 | 181篇 |
预防医学 | 22523篇 |
眼科学 | 7317篇 |
药学 | 22854篇 |
中国医学 | 825篇 |
肿瘤学 | 16415篇 |
出版年
2021年 | 2574篇 |
2019年 | 2749篇 |
2018年 | 4546篇 |
2017年 | 3563篇 |
2016年 | 3943篇 |
2015年 | 4202篇 |
2014年 | 5299篇 |
2013年 | 8647篇 |
2012年 | 11040篇 |
2011年 | 11562篇 |
2010年 | 7041篇 |
2009年 | 6076篇 |
2008年 | 10428篇 |
2007年 | 11309篇 |
2006年 | 11000篇 |
2005年 | 10446篇 |
2004年 | 9994篇 |
2003年 | 9473篇 |
2002年 | 9013篇 |
2001年 | 14008篇 |
2000年 | 14472篇 |
1999年 | 11844篇 |
1998年 | 3155篇 |
1997年 | 2909篇 |
1996年 | 2721篇 |
1995年 | 2652篇 |
1994年 | 2428篇 |
1992年 | 8403篇 |
1991年 | 8550篇 |
1990年 | 8350篇 |
1989年 | 8178篇 |
1988年 | 7428篇 |
1987年 | 7167篇 |
1986年 | 6811篇 |
1985年 | 6633篇 |
1984年 | 4892篇 |
1983年 | 4216篇 |
1982年 | 2560篇 |
1979年 | 4503篇 |
1978年 | 3277篇 |
1977年 | 2780篇 |
1976年 | 2541篇 |
1975年 | 2872篇 |
1974年 | 3381篇 |
1973年 | 3388篇 |
1972年 | 3139篇 |
1971年 | 2969篇 |
1970年 | 2873篇 |
1969年 | 2597篇 |
1968年 | 2562篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
3.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
4.
Anne-Sophie Worm Fenger Markus Harboe Olsen Maria Louise Fabritius Christian Gunge Riberholt Kirsten Møller 《Acta anaesthesiologica Scandinavica》2023,67(2):240-247
Background
Hyperglycaemia is common in patients with acute brain injury admitted to an intensive care unit (ICU). Many studies have found associations between development of hyperglycaemia and increased mortality in hospitalised patients. However, the optimal target for blood glucose control is unknown. We want to conduct a systematic review with meta-analysis and trial sequential analysis to explore the beneficial and harmful effects of restrictive versus liberal glucose control on patient outcomes in adults with severe acute brain injury.Methods
We will systematically search medical databases including CENTRAL, Embase, MEDLINE and trial registries. We will search the following websites for ongoing or unpublished trials: http://www.controlled-trials.com/ , http://www.clinicaltrials.gov/ , www.eudraCT.com , http://centerwatch.com/ , The Cochrane Library's CENTRAL, PubMed, EMBASE, Science Citation Index Expanded and CINAHL. Two authors will independently review and select trials and extract data. We will include randomised trials comparing levels of glucose control in our analyses and observational studies will be included to address potential harms. The primary outcomes are defined as all-cause mortality, functional outcome and health-related quality of life. Secondary outcomes include serious adverse events including hypoglycaemia, length of ICU stay and duration of mechanical ventilation, and explorative outcomes including intracranial pressure and infection. Trial Sequential Analysis will be used to investigate the risk of type I error due to repetitive testing and to further explore imprecision. Quality of trials will be evaluated using the Cochrane Risk of Bias tool, and quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.Discussion
The results of the systematic review will be disseminated through peer-reviewed publication. With the review, we hope to inform future randomised clinical trials and improve clinical practice. 相似文献5.
Tengzhi Liu Kathrine Røe Redalen Morten Karlsen 《Journal of labelled compounds & radiopharmaceuticals》2022,65(7):191-202
Cyclotron-produced copper-64 radioisotope tracers offer the possibility to perform both diagnostic investigation by positron emission tomography (PET) and radiotherapy by a theranostic approach with bifunctional chelators. The versatile chemical properties of copper add to the importance of this isotope in medicinal investigation. [64Cu][Cu (ATSM)] has shown to be a viable candidate for imaging of tumor hypoxia; a critical tumor microenvironment characteristic that typically signifies tumor progression and resistance to chemo-radiotherapy. Various production and radiosynthesis methods of [64Cu][Cu (ATSM)] exist in labs, but usually involved non-standardized equipment with varying production qualities and may not be easily implemented in wider hospital settings. [64Cu][Cu (ATSM)] was synthesized on a modified GE TRACERlab FXN automated synthesis module. End-of-synthesis (EOS) molar activity of [64Cu][Cu (ATSM)] was 2.2–5.5 Ci/μmol (HPLC), 2.2–2.6 Ci/μmol (ATSM-titration), and 3.0–4.4 Ci/μmol (ICP-MS). Radiochemical purity was determined to be >99% based on radio-HPLC. The final product maintained radiochemical purity after 20 h. We demonstrated a simple and feasible process development and quality control protocols for automated cyclotron production and synthesis of [64Cu][Cu (ATSM)] based on commercially distributed standardized synthesis modules suitable for PET imaging and theranostic studies. 相似文献
6.
7.
8.
9.
10.